Close Menu

Precision Oncology News

There is a dearth of standardized criteria for biomarker testing quality and access across the region, according to the report.

The company was cleared to begin a Phase I/II trial of its lead candidate, a therapeutic vaccine that can potentially treat and prevent recurrence of KRAS-mutated cancers.